2022

Hay, J. et al. (2022) PKCβ facilitates leukemogenesis in chronic lymphocytic leukaemia by promoting constitutive BCR-mediated signalling. Cancers, 14(23), 6006. (doi: 10.3390/cancers14236006) (PMID:36497487) (PMCID:PMC9735720)

Parry, N., Busch, C., Aßmann, V., Cassels, J., Hair, A., Helgason, G. V. , Wheadon, H. and Copland, M. (2022) BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia. Cell Death Discovery, 8, 457. (doi: 10.1038/s41420-022-01211-1) (PMID:36379918) (PMCID:PMC9666353)

2020

Kinstrie, R. et al. (2020) CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. Leukemia, 34(6), pp. 1613-1625. (doi: 10.1038/s41375-019-0684-5) (PMID:31896780) (PMCID:PMC7272220)

2019

Malik, N. , Dunn, K. M., Cassels, J., Hay, J. , Estell, C., Sansom, O. J. and Michie, A. M. (2019) mTORC1 activity is essential for erythropoiesis and B cell lineage commitment. Scientific Reports, 9, 16917. (doi: 10.1038/s41598-019-53141-1) (PMID:31729420) (PMCID:PMC6858379)

Hay, J. , Moles, M. W., Cassels, J. and Michie, A. M. (2019) Subcellular fractionation of primary chronic lymphocytic leukemia cells to monitor nuclear/ cytoplasmic protein trafficking. Journal of Visualized Experiments(152), e60426. (doi: 10.3791/60426) (PMID:31710039)

2017

Tarafdar, A. et al. (2017) CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression. Blood, 129(2), pp. 199-208. (doi: 10.1182/blood-2016-09-742049) (PMID:27793879) (PMCID:PMC5305055)

2016

Horne, G. A. , Morrison, H., Campbell, V., Kinstrie, R., Cassels, J., Hair, A., Vetrie, D. , Wheadon, H. , Holyoake, T. L. and Copland, M. (2016) Notch Pathway Activation Targets Leukemic Stem Cells in Chronic-Phase Chronic Myeloid Leukemia (CP-CML). American Society of Hematology 58th Annual Meeting, San Diego, CA, USA, 3-6 Dec 2016.

Scott, M. T. et al. (2016) Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition. Cancer Discovery, 6(11), pp. 1248-1257. (doi: 10.1158/2159-8290.CD-16-0263) (PMID:27630125) (PMCID:PMC6538532)

Michie, A.M. , Tarafdar, A., Gallipoli, P., Pellicano, F., Hopcroft, L. , Korfi, K., Cassels, J., Jorgensen, H.J. , Vetrie, D. and Holyoake, T.L. (2016) CML Cells Actively Evade Host Immune Surveillance Through Cytokine-Mediated Downregulation of MHC-I I Expression. 36th World Congress of the International Society of Hematology, Glasgow, Scotland, 18-21 Apr 2016. p. 117. (doi: 10.1111/bjh.14019)

2013

Abraham, S., Hopcroft, L. , Carrick, E., Williamson, A., Pierce, A., Cassels, J., Pellicano, F., Whetton, A. and Holyoake, T. L. (2013) p53 and c-Myc are critical signaling hubs that maintain chronic myeloid leukemia. In: 55th American Society of Hematology Annual Meeting and Exposition, New Orleans, LA, USA, 7-10 Dec 2013, p. 1465.

Articles

Hay, J. et al. (2022) PKCβ facilitates leukemogenesis in chronic lymphocytic leukaemia by promoting constitutive BCR-mediated signalling. Cancers, 14(23), 6006. (doi: 10.3390/cancers14236006) (PMID:36497487) (PMCID:PMC9735720)

Parry, N., Busch, C., Aßmann, V., Cassels, J., Hair, A., Helgason, G. V. , Wheadon, H. and Copland, M. (2022) BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia. Cell Death Discovery, 8, 457. (doi: 10.1038/s41420-022-01211-1) (PMID:36379918) (PMCID:PMC9666353)

Kinstrie, R. et al. (2020) CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. Leukemia, 34(6), pp. 1613-1625. (doi: 10.1038/s41375-019-0684-5) (PMID:31896780) (PMCID:PMC7272220)

Malik, N. , Dunn, K. M., Cassels, J., Hay, J. , Estell, C., Sansom, O. J. and Michie, A. M. (2019) mTORC1 activity is essential for erythropoiesis and B cell lineage commitment. Scientific Reports, 9, 16917. (doi: 10.1038/s41598-019-53141-1) (PMID:31729420) (PMCID:PMC6858379)

Hay, J. , Moles, M. W., Cassels, J. and Michie, A. M. (2019) Subcellular fractionation of primary chronic lymphocytic leukemia cells to monitor nuclear/ cytoplasmic protein trafficking. Journal of Visualized Experiments(152), e60426. (doi: 10.3791/60426) (PMID:31710039)

Tarafdar, A. et al. (2017) CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression. Blood, 129(2), pp. 199-208. (doi: 10.1182/blood-2016-09-742049) (PMID:27793879) (PMCID:PMC5305055)

Scott, M. T. et al. (2016) Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition. Cancer Discovery, 6(11), pp. 1248-1257. (doi: 10.1158/2159-8290.CD-16-0263) (PMID:27630125) (PMCID:PMC6538532)

Conference or Workshop Item

Horne, G. A. , Morrison, H., Campbell, V., Kinstrie, R., Cassels, J., Hair, A., Vetrie, D. , Wheadon, H. , Holyoake, T. L. and Copland, M. (2016) Notch Pathway Activation Targets Leukemic Stem Cells in Chronic-Phase Chronic Myeloid Leukemia (CP-CML). American Society of Hematology 58th Annual Meeting, San Diego, CA, USA, 3-6 Dec 2016.

Michie, A.M. , Tarafdar, A., Gallipoli, P., Pellicano, F., Hopcroft, L. , Korfi, K., Cassels, J., Jorgensen, H.J. , Vetrie, D. and Holyoake, T.L. (2016) CML Cells Actively Evade Host Immune Surveillance Through Cytokine-Mediated Downregulation of MHC-I I Expression. 36th World Congress of the International Society of Hematology, Glasgow, Scotland, 18-21 Apr 2016. p. 117. (doi: 10.1111/bjh.14019)

Conference Proceedings

Abraham, S., Hopcroft, L. , Carrick, E., Williamson, A., Pierce, A., Cassels, J., Pellicano, F., Whetton, A. and Holyoake, T. L. (2013) p53 and c-Myc are critical signaling hubs that maintain chronic myeloid leukemia. In: 55th American Society of Hematology Annual Meeting and Exposition, New Orleans, LA, USA, 7-10 Dec 2013, p. 1465.